Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes

Sponsor
Michigan State University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05564663
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
300
1
2
30.9
9.7

Study Details

Study Description

Brief Summary

The purpose of this study is to learn whether a mobile health application (mHealth App) for posttraumatic stress disorder (PTSD) with brief support can help individuals who are in treatment for alcohol problems.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: PTSD Coach App + Brief Support
  • Behavioral: Enhanced Usual Care (EUC)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
May 31, 2025
Anticipated Study Completion Date :
May 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: PTSD Coach App + Brief Support

PTSD Coach App + Brief Support will include brief instruction and support for the use of the PTSD Coach App developed by the study team. The PTSD Coach App incorporates evidence-based assessment, psychoeducation, and self-management strategies for PTSD symptoms that are customizable to the user.

Behavioral: PTSD Coach App + Brief Support
PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).

Active Comparator: Enhanced Usual Care (EUC)

EUC will include brief psychoeducation regarding PTSD and alcohol use disorder (AUD) and resources for PTSD-related mental health treatment.

Behavioral: Enhanced Usual Care (EUC)
EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.

Outcome Measures

Primary Outcome Measures

  1. PTSD Checklist for DSM-5 (PCL-5) Change [Baseline, 1-, 3-, 6-, and 12-months]

    The PCL-5 is a 20-item, self-reported measure that assesses the 20 DSM-5 symptoms of PTSD. Each symptom is measured on a 0-4 scale, with higher values indicating greater severity. Total scale scores range from 0 to 80.

  2. Timeline Followback (TLFB) for Alcohol Change [Baseline, 1-, 3-, 6-, and 12-months]

    The TLFB assessment method will be used to assess alcohol use in the past 30-days.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Currently in addictions treatment

  • Meet criteria for a current Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) AUD

  • A score of 33 or greater on the PTSD Checklist (PCL-5)

  • Own a smart phone or other type of Wi-Fi-enabled device with App capabilities

Exclusion Criteria:
  • Injection drug use in the past year

  • Patients who are unable to speak and/or understand English

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pine Rest Christian Mental Health Services Grand Rapids Michigan United States 49548

Sponsors and Collaborators

  • Michigan State University
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

  • Principal Investigator: Kipling Bohnert, Michigan State University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kipling Bohnert, Associate Professor, Michigan State University
ClinicalTrials.gov Identifier:
NCT05564663
Other Study ID Numbers:
  • STUDY00006258
  • R01AA028213
First Posted:
Oct 3, 2022
Last Update Posted:
Oct 3, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 3, 2022